Carboplatin/Pemetrexed Regimen

Identifier: CI-DRUG-00000142
Entity page: /drug/carboplatin-pemetrexed-regimen ↗
Edges: 9

Neighbours: 6 cancers3 trials
Drawn: 9 of 9 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Carboplatin/Pemetrexed Regimen investigated in trials for …INVESTIGATED_IN_TRIALSderived6 of 6
→ investigated in trials for	Lung Non-Small Cell Carcinoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

Carboplatin/Pemetrexed Regimen studied in …STUDIED_INderived3 of 3
→ studied in	NCT05431270Phase 1/Phase 2 · recruiting Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) · 3 trials list this drug (2 active)	—	—	Lung Non-Small Cell Carcinoma,Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03307785Phase 1 · completed Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 · 3 trials list this drug (2 active)	—	—	Neoplasm,Malignant Neoplasm,Solid Neoplasm+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06784791Phase 2 · recruiting Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) · 3 trials list this drug (2 active)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →

Carboplatin/Pemetrexed Regimen studied in …STUDIED_INderived3 of 3

→ studied in

NCT05431270Phase 1/Phase 2 · recruiting

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) · 3 trials list this drug (2 active)

—

Lung Non-Small Cell Carcinoma,Pancreatic Ductal Adenocarcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT03307785Phase 1 · completed

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 · 3 trials list this drug (2 active)

—

Neoplasm,Malignant Neoplasm,Solid Neoplasm+1

Observed

clinicaltrials

graph →

→ studied in

NCT06784791Phase 2 · recruiting

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) · 3 trials list this drug (2 active)

—

Malignant Lung Neoplasm

Observed

clinicaltrials

graph →

Radial view

Every edge, grouped by relationship

Paths